Request availability and a quotation for your required quantity and destination.
| Product | Retatrutide 30 mg - Reta 30 Pen |
|---|---|
| Categories | Weight Loss |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Catalogue category: Weight Loss
Regulatory status: Investigational; not FDA-approved
Listing verification: Manufacturer, formulation and dose-delivery details not independently verified
Retatrutide is designed to activate glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. Phase 3 research, including TRIUMPH-1, evaluates its efficacy and safety in obesity. Investigational clinical results do not verify the authenticity or safety of independently marketed products.
The stated 30 mg is a catalogue descriptor, not a medically validated dosing schedule. No authenticity, approved manufacturer, sterile fill, delivery-device accuracy or lawful retail authorization has been confirmed for this listing. Do not infer that an unverified pen is the studied investigational product.
Trial research has reported gastrointestinal adverse effects. Unapproved injectable products add risks involving contamination, composition, dosing and storage. Anyone considering obesity treatment should seek licensed clinical care and regulatory-approved alternatives appropriate to their medical history.
Retatrutide is an investigational medicine that activates GLP-1, GIP and glucagon receptors.
No. As of October 2026 it has not received FDA approval for any indication.
No approval or manufacturer authenticity has been established for the listed Reta 30 Pen.
The FDA states retatrutide is unapproved and cannot legally be used in compounding in the United States. Avoid unverified retail injectable products.
The listing states 30 mg but does not verify concentration, dose delivery, manufacturer, sterility or any authorized dosing instructions.
Retatrutide targets three receptors, while semaglutide acts on GLP-1; this does not establish approval or safe interchangeability.
Yes. Clinical trials have studied efficacy and safety, but study results do not confer regulatory approval.
Gastrointestinal adverse effects such as nausea, vomiting and diarrhea have been reported; long-term risks remain under evaluation.
Do not self-inject investigational or unverifiable products. A legitimate trial operates under clinical protocols and oversight.
Review official regulatory communications and registered clinical trials, including ClinicalTrials.gov.
Information only. Cureiva should independently verify the product identity and applicable laws before making any supply representation. No independent clinician review is claimed.